StockNews.AI
NBIX
StockNews.AI
4 hrs

Neurocrine Biosciences to Present at Upcoming Investor Conferences in September

1. Neurocrine Biosciences will attend four investor conferences in September. 2. CFO, CCO, and VP of IR will speak at the Cantor Conference. 3. CEO and CMO will present at the Morgan Stanley Healthcare Conference. 4. Presentations include Baird Global Healthcare and TD Cowen's Neuropsychiatry Summit. 5. Webcasts will be accessible live and archived for one month.

9m saved
Insight
Article

FAQ

Why Bullish?

Participation in key conferences may enhance investor confidence, leading to positive price movement. Historical contexts show that such corporate engagements can effectively elevate stock awareness and valuations.

How important is it?

The scheduled presentations can impact investor perceptions and engagement with the stock, indicating strong communication strategies from the company.

Why Short Term?

Immediate investor sentiment is likely impacted due to upcoming presentations. Similar past events have shown quick reactions in stock price shortly after major corporate communications.

Related Companies

ABBV

SAN DIEGO, Aug. 26, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) will participate at four investor conferences in September.

  • Chief Financial Officer Matt Abernethy, Chief Commercial Officer Eric Benevich, and Vice-President of Investor Relations Todd Tushla will present at the Cantor Global Healthcare Conference 2025 at 1:00 p.m. ET on Wednesday, September 3, 2025.
  • Chief Executive Officer Kyle Gano and Chief Medical Officer Sanjay Keswani will present at the Morgan Stanley 23rd Annual Global Healthcare Conference at 10:45 a.m. ET on Tuesday, September 9, 2025.
  • Chief Executive Officer Kyle Gano, Chief Medical Officer Sanjay Keswani, and Vice-President of Investor Relations Todd Tushla will present at the Baird 2025 Global Healthcare Conference at 10:15 a.m. ET on Wednesday, September 10, 2025.
  • Chief Executive Officer Kyle Gano and Vice-President of Investor Relations Todd Tushla will present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry and Epilepsy Virtual Summit at 12:40 p.m. ET on Wednesday, September 17, 2025.

The live webcasts can be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcasts will be available on the website approximately one hour after the conclusion of the events and will be archived for approximately one month.

About Neurocrine Biosciences

Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X and Facebook.

(*in collaboration with AbbVie)

NEUROCRINE, the NEUROCRINE BIOSCIENCES Logo and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-upcoming-investor-conferences-in-september-302539287.html

SOURCE Neurocrine Biosciences, Inc.

Related News